ArticleEClinicalMedicine2025

Pegylated granulocyte colony-stimulating factor primary prophylaxis versus no prophylaxis in patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: a randomized, open-label, multicenter, phase 2 trial.

Choong-Kun Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.